Pneumonia, caused by bacterial and/or viral etiology, is the leading cause of death in children worldwide. Preceding viral illness, linked to influenza infection, is a primary risk factor associated with secondary bacterial pneumonia. Influenza infection is an annual, seasonal cause of morbidity and mortality throughout the world. Severe influenza pneumonia is often exacerbated by bacterial infection resulting in poor patient outcomes in those with preexisting lung morbidity and in previously healthy individuals. The pandemic potential of influenza viruses heightens the importance of understanding disease pathogenesis. Further, secondary bacterial pneumonia with Staphylococcus aureus is increasing in prevalence, while antibiotic resistance continues to propagate. The focus of this application is upon understanding the influenza-induced mechanisms of susceptibility to bacterial super-infection, the leading cause of death during pandemic outbreaks. During the previous funding period, our laboratory has identified suppression of bacterial-induced Type 17 immune responses by preceding influenza as a critical susceptibility mechanism. We have published extensively in the area of elucidating aberrant host defense pathways in this context. In this renewal application, we will build upon our ongoing work with three highly novel Aims derived from the original focus. We hypothesize that S. aureus-induced Type 17 innate immune activation is negatively regulated by influenza-induced STAT2 signaling and the Asc inflammasome. Further, we propose that exogenous antimicrobial peptide (AMP) therapy presents a novel therapeutic strategy in influenza, bacterial super-infection.
In Aim 1 we will determine the mechanism(s) by which STAT2 signaling impairs anti-bacterial host defense against S. aureus during influenza super-infection.
Aim 2 will focus on the mechanism(s) by which Asc inflammasome knockout mice are protected from exacerbation of secondary S. aureus infection.
In Aim 3 we will investigate the mechanism of AMP production and evaluate the therapeutic potential of exogenous AMPs during influenza, S. aureus super- infection. The proposed studies will further our understanding of how influenza impairs subsequent immunity against S. aureus (Aim 1), how the immune response to S. aureus is initiated in the lung (Aim 2), and test novel therapeutic approaches for controlling post-influenza secondary bacterial pneumonia (Aim 3). Our overriding goal is to understand the critical mechanism(s) of susceptibility to influenza, S. aureus super- infection and provide novel treatment targets in a pre-clinical model of disease.

Public Health Relevance

The influenza virus infects millions globally each year and in some cases is complicated with bacterial super-infection, which can result in severe illness and/or death. This study addresses the mechanisms by which influenza makes the lung more susceptible to later bacterial infection. This proposal defines the molecular pathways by which influenza leads to suppressed Staphylococcus aureus host defense and attempts to identify novel therapeutic targets to improve patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL107380-06A1
Application #
9308220
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Caler, Elisabet V
Project Start
2012-01-01
Project End
2021-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
6
Fiscal Year
2017
Total Cost
$387,813
Indirect Cost
$137,813
Name
University of Pittsburgh
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Shinde, Apurva; Luo, Jiadi; Bharathi, Sivakama S et al. (2018) Increased mortality from influenza infection in long-chain acyl-CoA dehydrogenase knockout mice. Biochem Biophys Res Commun 497:700-704
Robinson, K M; Ramanan, K; Clay, M E et al. (2018) Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection. Mucosal Immunol 11:199-208
Robinson, Keven M; Ramanan, Krishnaveni; Clay, Michelle E et al. (2018) The inflammasome potentiates influenza/Staphylococcus aureus superinfection in mice. JCI Insight 3:
Manni, Michelle L; Mandalapu, Sivanarayana; Salmeron, Andres et al. (2017) Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease. Sci Rep 7:43139
Lee, Benjamin; Gopal, Radha; Manni, Michelle L et al. (2017) STAT1 Is Required for Suppression of Type 17 Immunity during Influenza and Bacterial Superinfection. Immunohorizons 1:81-91
Treerat, P; Prince, O; Cruz-Lagunas, A et al. (2017) Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol 10:1069-1081
Zhang, Hongbo; Luo, Jiadi; Alcorn, John F et al. (2017) AIM2 Inflammasome Is Critical for Influenza-Induced Lung Injury and Mortality. J Immunol 198:4383-4393
Pociask, Derek A; Robinson, Keven M; Chen, Kong et al. (2017) Epigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection. Am J Pathol 187:851-863
Manni, Michelle L; Mandalapu, Sivanarayana; McHugh, Kevin J et al. (2016) Molecular Mechanisms of Airway Hyperresponsiveness in a Murine Model of Steroid-Resistant Airway Inflammation. J Immunol 196:963-77
Shankar, J; Nguyen, M H; Crespo, M M et al. (2016) Looking Beyond Respiratory Cultures: Microbiome-Cytokine Signatures of Bacterial Pneumonia and Tracheobronchitis in Lung Transplant Recipients. Am J Transplant 16:1766-78

Showing the most recent 10 out of 29 publications